Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 10, 2017. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific equity transactions.
| Transaction Date | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| November 9, 2017 | Ordinary Shares (25 pence each) | £13.6418 | 152 shares (aggregate) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine share acquisitions by nine senior executives, including the CEO, CFO, and President of R&D, executed on the London Stock Exchange.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with regulatory requirements.
Key Facts for Investor Verification
- Transaction Type: All reported transactions were acquisitions of Ordinary Shares under the Share Reward Plan, consisting of partnership and matching shares.
- Participants: Nine PDMRs participated, including Ms. E. Walmsley (CEO), Mr. S. Dingemans (CFO), and Dr. P. J. T. Vallance (President, R&D).
- Valuation: All shares were acquired at a uniform price of £13.6418 per share.
- Volume: Individual acquisitions ranged from 18 to 20 shares per executive.
- Market: Transactions were conducted on the London Stock Exchange (XLON).